Maria Mazurkiewicz-Bełdzińska outlines a pooled analysis of data from the FIREFISH, SUNFISH, and JEWELFISH trials, which demonstrates that risdiplam has a favorable benefit–risk profile in patients with spinal muscular atrophy (3:42).
Maria Mazurkiewicz-Bełdzińska outlines a pooled analysis of data from the FIREFISH, SUNFISH, and JEWELFISH trials, which demonstrates that risdiplam has a favorable benefit–risk profile in patients with spinal muscular atrophy (3:42).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Deputy Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.
